karmma-4: ide-cel for newly diagnosed high-risk multiple myeloma
Published 3 years ago • 252 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:58
karmma study shows improved qol in patients with r/r multiple myeloma treated with ide-cel
-
2:16
updates from the karmma-3 trial: safety profile of ide-cel in tce r/r multiple myeloma
-
2:11
current treatment landscape of newly diagnosed multiple myeloma
-
5:16
updated karmma results: ide-cel in r/r myeloma
-
1:47
abnormal serum immunofixation patterns following bcma car-t in multiple myeloma
-
6:23
results of maintenance therapy in high-risk myeloma patients | ajay nooka, md, mph, facp | asco 2023
-
4:04
the future of myeloma treatment and the possibility of cure
-
4:18
myeloma awareness week 2021: don't miss myeloma
-
3:23
bringing car-t therapy in earlier lines of treatment in myeloma: karmma-3, cartitude-4 & cartitude-6
-
3:54
karmma-3: pros in patients with tce r/r myeloma treated with ide-cel vs standard regimens
-
2:25
cartitude-5: vrd cilta-cel or rd in newly diagnosed multiple myeloma
-
1:13
longitudinal findings from the karmma trial: improved qol in patients treated with ide-cel
-
1:23
management of high-risk newly diagnosed mm
-
2:46
managing patients with high-risk myeloma
-
5:05
patient-reported outcomes in cartitude-4: cilta-cel vs soc in r/r multiple myeloma
-
8:16
results from cartitude-4: cilta-cel for lenalidomide-refractory multiple myeloma
-
1:57
using molecular abnormalities for risk stratification in multiple myeloma at the time of diagnosis
-
1:47
cilta-cel in earlier lines of therapy for r/r multiple myeloma
-
2:49
defining high-risk myeloma
-
2:06
subanalysis of the karmma trial: predicting complete response to car-t in multiple myeloma
-
1:55
karmma-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma